Drug Trial Radar · NCT06767748
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
620
Planned (sponsor's estimate)
Start
Feb 15, 2025
Primary completion
Feb 7, 2026
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Degludec with or without Non-Insulin Antidiabetic Agents in subjects with Type 2 Diabetes Mellitus (T2DM) treated with basal insulin.
Conditions
- Diabetes
Interventions
GZR4Drug
GZR4 s.c., once-weekly,treat-to-target dose
insulin degludecDrug
insulin degludec s.c.,once-daily,treat-to-target dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: From baseline (week 0) to week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gan & Lee Pharmaceuticals Shandong Co., Ltd.
Linyi, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.